Figure 2. Assessing the chemosensitizing potential of lymphoma defective in PCNA ubiquitination.

(A) Schematic representation of the in vitro modification of lymphoma cells. (B) In vitro sensitivity assay of WT (DDT^P) and PCNA^K164R mutant (DDT^D) lymphomas to increasing CsPt doses. (C) Schematic representation of the in vivo approach. (D) In vivo bioluminescence imaging quantification as Flux (photons per second) of transplanted WT tumors (n = 8) control (left) or treated in response to 6 mg/kg CsPt treatment every two weeks (n = 9) (right) lymphomas over days. (E) In vivo bioluminescence imaging quantification represented as Flux of transplanted DDT-defective (n = 9) lymphomas. (F) In vivo bioluminescence imaging quantification represented as flux of transplanted DDT-defective (n = 10) lymphomas in response to 6 mg/kg CsPt treatment every two weeks. Each colored line represents a different mouse. Mice have been grouped in different graphs on the basis of the response to CsPt.